

Corporate Action Notice

November 29, 2016

Ratio Change

Therapix Biosciences Ltd.

DR CUSIP: 88339A104 / **DR ISIN:** US88339A1043

DR Ticker Symbol: THXBY

Ratio: (DS: Underlying Shares): 1:20

BNY Mellon, at the direction of Therapix Biosciences Ltd. ("Therapix") is announcing a ratio change on the Depositary Receipt ("DR") Program from one (1) Depositary Share ("DS") representing twenty (20) Ordinary shares to one (1) DS representing forty (40) Ordinary shares.

The ratio change will result in a reverse stock split on the Therapix DSs on a basis of 1 new DS for every 2 old DSs held. The ordinary shares of Therapix will not be affected by this change.

Effective December 9, 2016, holders of Therapix will be required on a mandatory basis to surrender their DRs to BNY Mellon for cancellation and exchange on a basis of one (1) 'NEW' DS (CUSIP# 88339A203) for every two (2) 'OLD' DSs (CUSIP# 88339A104). Only whole DSs will be distributed BNY Mellon will attempt to sell any fractional DSs and distribute the cash proceeds.

BNY MELLON HAS ESTABLISHED THE FOLLOWING DATE AND RATES FOR THIS CORPORATE ACTION:

Effective Date: December 9, 2016

Exchange Rate: 1 New DS for 2 Old DSs

Old CUSIP: 88339A104

Old Ratio: 1 DS: 20 Ordinary Shares

New CUSIP: 88339A203

New Ratio: 1 DS: 40 Ordinary Shares

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

NEW YORK

Ravi Davis

Richard J Maehr

+ 1 212 815 2267

adrdesk@bnymellon.com

LONDON

Jacek Jankowski

Vice President

+ 44 207 163 7427

jacek.jankowski@bnymellon.com

BNY Mellon is providing this information for general informational purposes only and does not warrant or guarantee the accuracy, timeliness or completeness of this information. BNY Mellon does not undertake any obligation to update or amend this information. BNY Mellon provides no advice, recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. BNY Mellon collects fees from Depositary Receipt ("DR") holders pursuant to the terms and conditions of the DRs. BNY Mellon may make payments to sponsored DR issuers to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses for services provided. BNY Mellon may pay a rebate to brokers in connection with unsponsored DR issuances. BNY Mellon may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. BNY Mellon may execute DR foreign currency transactions itself or through its affiliates and in such cases it acts as principal counterparty and not as agent, advisor, broker or fiduciary. BNY Mellon has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY Mellon earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY Mellon to determine DR conversion rates is available to registered Owners upon request or at https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset_upload_file49220_197380.pdf. Depositary Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon, and are subject to investment risks.



BNY MELLON